Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C32H35N7O4 · 2HCl
CAS Number:
Molecular Weight:
654.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(NCC1=CC=C(C=C1C)C(N2CC3=C(NC4=CC=CC=C24)N(N=C3)C)=O)N5CCN(CC5)CC6=CC(O)=CC(O)=C6
InChI
1S/C32H35N7O4.2ClH/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22;;/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43);2*1H
InChI key
OTFWXMFLPMUDFP-UHFFFAOYSA-N
Biochem/physiol Actions
Non-peptide oxytocin receptor (OTR) agonist and vasopressin V1a receptor (V1aR) antagonist.
WAY-267464 is a non-peptide drug with a novel mechanism of action (MOA) to treat psychosis and schizophrenia.
WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist (EC50 = 61-881 nM; Ki = 58-978 nM) that, unlike oxytocin (OT), displays antagonist instead of agonist activity toward vasopressin V1a receptor/V1aR (IC50 = 613 nM; Ki = 27-113 nM). WAY-267464 exhibits OT-like anxiolytic effects in assays measuring both behavioral (33% increase in punished crossing by 10 mg/mL ip or 10 μg/mouse icv in four-plate tests; 75% increased open quadrants stay by 3 μg/mouse icv in elevated zero maze) and autonomic (47% higher stress-induced hyperthermia by 10 μg/mouse icv) parameters of the anxiety response. Similar to the antipsychotic-like effects reported for OT, WAY-267464 also reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine. Unlike OT, WAY-267464 does not affect immobility in mouse tail suspension test.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Robert H Ring et al.
Neuropharmacology, 58(1), 69-77 (2009-07-21)
The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression. The utility of synthetic
William T Jorgensen et al.
European journal of medicinal chemistry, 108, 730-740 (2016-01-08)
A previously identified, non-peptidic oxytocin (OT) receptor agonist WAY-267,464 (1) and nine novel derivatives (3, 4a-7a, 4b-7b) were synthesised and evaluated in vitro with the aim of systematically exploring hydrogen bonding interactions and ligand flexibility. All analogues were subjected to competition
C Hicks et al.
Journal of neuroendocrinology, 24(7), 1012-1029 (2012-03-17)
Previous research suggests that the nonpeptide oxytocin receptor (OTR) agonist WAY 267,464 may only partly mimic the effects of oxytocin in rodents. The present study further explored these differences and related them to OTR and vasopressin 1a receptor (V(1a) R)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2223-5MG | 04061835494712 |
| SML2223-25MG | 04061835494705 |